TRANSFUSION MEDICINE PROTOCOLS

CMV Immunoglobulin VF

This document should be read in conjunction with the Disclaimer

AIM	To describe the indication, ordering, administration and documentation of CMV Immunoglobulin VF
DESCRIPTION	CMV Immunoglobulin-VF Human Cytomegalovirus (CMV) Immunoglobulin, solution for intravenous injection
SPECIFICATIONS	55-65 mg/ml plasma proteins (at least 98% IgG). 292mmol/L of maltose. Manufactured from pooled human plasma. CMV Immunoglobulin VF Product Information
VIAL SIZE	50mL/vial. CMV Ig activity 1.5 million units per vial.
INDICATIONS	Prevention of CMV infection in bone marrow, renal, cardiac and liver transplant recipients who are CMV antibody negative where the donor is CMV antibody positive. Therapy in patients with established CMV infection e.g. CMV pneumonitis. The WNHS Infection Control Manual is available for reference
CONTRAINDICATIONS AND PRECAUTIONS	CMV Immunoglobulin–VF is contra-indicated in individuals who have a true anaphylactic reaction to a human immunoglobulin preparation. ⚠CAUTION Individuals with IgA deficiency should not receive the product, unless they have no circulating anti-IgA antibodies.
CONSUMER INFORMATION	CMV Immunoglobulin-VF Consumer Medical Information
CONSENT	Written consent is required as CMV Immunoglobulin is manufactured from pooled human plasma. Refer to Transfusion Medicine Protocol WNHS Blood Product Prescription, Informed Consent. And Refusal

DOSE	Dose is dependent on patient's weight and clinical indication. Refer to Consult Immunologist or Haematologist for advice.
ORDERING	CMV Immunoglobulin may be ordered on a named patient basis from the Transfusion Medicine Unit. The product will have a peel off product label which can be stuck on the transfusion medicine record form (MR735).
ADMINISTRATION	• Two staff to perform checks as per the Clinical Practice Manual, WNHS Pharmacy Medication Checking and Administration processes. Check Issue label and patient ID. Check right patient, right product, right dose – prescription matches product supplied. If not identical, contact TMU and prescribing doctor. • The product must be used immediately after opening. Any unused solution must be discarded. • Do not use the product if it appears turbid or cloudy. • Allow product to reach room temperature before administration. • Administer intravenously only and separately from other intravenous fluids. • Must be administered using a pump device via standard IV giving set for designated pump. • Can be administered diluted or undiluted. See product information for more information. • ⚠CAUTION Maltose may interfere in blood glucose testing. Refer to CMV Immunoglobulin VF Product Information for more information. • Rate: Commence the infusion at a rate of 1mL per minute. • After 15 minutes the rate may gradually be increased to a maximum of 3 to 4mLs per minute over a further 15 minutes. Refer to current product information sheet.
OBSERVATIONS	Undertake observations as for all blood products. Vital signs (temperature, pulse, respiration, blood pressure) must be recorded on the observation chart in the medical record. • Before the start of each infusion. • At 15 minutes from start of infusion.

	• Thereafter, hourly throughout the infusion. • On the completion of infusion. Observe for signs of adverse reactions – refer to CMV Immunoglobulin VF Product Information
ADVERSE REACTIONS	Adverse reactions are usually rate related & are most likely to occur within the first hour. Refer to CMV Immunoglobulin VF Product Information for more information on adverse reactions. Any adverse reaction should be reported to the Clinical Haematologist and TMU. Refer to WNHS Management of Transfusion Reactions and Adverse Events, as a guide to further treatment and management of the patient.
DOCUMENTATION	A record should be kept in the patient's history of the following: • The date and time of infusion • Patients observations and condition during the infusion • Amount given • The batch number and expiry date of each bottle used (place a sticker with the batch number on the Transfusion Medicine Record sheet MR735). This information is important should the patient have a reaction to the infusion or if there is a need to trace recipients of certain batch numbers at a later date.
For further information, refer to product insert Return product to TMU immediately if no longer required. Product should be used for intended patient (issue label) only.	

References

- Australian Red Cross Blood Service – Blood products and transfusion practice for health professionals. Australian Red Cross website
- Australian Red Cross Blood Service – Plasma Immunoglobulins http://www.transfusion.com.au/blood_products/fractionated_plasma/immunoglobulins
- The Australian Blood Service (ARCBS) Blood Component Information http://www.transfusion.com.au/sites/default/files/BCI%202009.pdf
- Flippin' Blood BloodSafe SA / ARCBS Second Edition June 2012 http://resources.transfusion.com.au/cdm/ref/collection/p16691coll1/id/20
- CSL Global CMV Immunoglobulin-VF

- National Safety and Quality Health Service Standards, October 2012. Standard 7: Blood and Blood Products

Related WNHS policies, procedures and guidelines

- WNHS Blood Product Prescription, Consent and Refusal
- WNHS Management of Transfusion Reactions and Adverse Events
- WNHS Pharmacy Medication Checking and Administration
- Neonatology Clinical Care Guidelines
- Obstetrics and Gynaecology Clinical Guidelines
- WNHS Pharmacy Medication Checking and Administration

File path:	WNHS.HAEM.CMVImmunoglobulinVF		
Keywords:	Blood Transfusion, Blood products, CMV Immunoglobulin VF, Cyto megalo virus immunoglobulin, administration of CMV immunoglobulin, plasma derived blood products. Blood bank, transfusion medicine unit, blood bank scientist		
Document owner:	Chair of KEMH Hospital Transfusion Committee		
Author / Reviewer:	Consultant Haematologist, Scientist in Charge Transfusion Medicine, KEMH Transfusion Coordinator		
Date first issued:	01 01 2005		
Last reviewed:	01 12 2015	Next review date:	01 02 2020
Endorsed by:	KEMH Hospital Transfusion Committee	Date:	01 02 2017
Standards Applicable:	NSQHS Standards: 1 Governance, 5 Patient ID/Procedure Matching, 7 Blood Products		
Printed or personally saved electronic copies of this document are considered uncontrolled. Access the current version from the WNHS website.			